Phase 1b Pilot Study of Atibuclimab (IC14) for Treatment of ST-Elevation Myocardial Infarction
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Atibuclimab (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors Implicit Bioscience
Most Recent Events
- 10 Feb 2025 Planned End Date changed from 1 Oct 2025 to 1 Jun 2026.
- 10 Feb 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Dec 2025.
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.